CN115190973B - 基于可溶性clec-2与血小板数的血小板活化测定方法 - Google Patents

基于可溶性clec-2与血小板数的血小板活化测定方法

Info

Publication number
CN115190973B
CN115190973B CN202180017311.7A CN202180017311A CN115190973B CN 115190973 B CN115190973 B CN 115190973B CN 202180017311 A CN202180017311 A CN 202180017311A CN 115190973 B CN115190973 B CN 115190973B
Authority
CN
China
Prior art keywords
concentration
platelet
platelets
sclec
clec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180017311.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115190973A (zh
Inventor
石仓宏恭
川村雅英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pu Heji
Original Assignee
LSI Medience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LSI Medience Corp filed Critical LSI Medience Corp
Publication of CN115190973A publication Critical patent/CN115190973A/zh
Application granted granted Critical
Publication of CN115190973B publication Critical patent/CN115190973B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202180017311.7A 2020-02-28 2021-02-26 基于可溶性clec-2与血小板数的血小板活化测定方法 Active CN115190973B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-032797 2020-02-28
JP2020032797 2020-02-28
PCT/JP2021/007273 WO2021172493A1 (ja) 2020-02-28 2021-02-26 可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法

Publications (2)

Publication Number Publication Date
CN115190973A CN115190973A (zh) 2022-10-14
CN115190973B true CN115190973B (zh) 2025-10-21

Family

ID=77491232

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180017311.7A Active CN115190973B (zh) 2020-02-28 2021-02-26 基于可溶性clec-2与血小板数的血小板活化测定方法

Country Status (6)

Country Link
US (1) US12590978B2 (https=)
EP (1) EP4113524A4 (https=)
JP (1) JP7546037B2 (https=)
KR (1) KR20220147624A (https=)
CN (1) CN115190973B (https=)
WO (1) WO2021172493A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4279606A4 (en) * 2021-01-13 2024-12-18 PHC Corporation Method for predicting risk for thrombosis in cancer patient using soluble clec2
EP4350350A4 (en) * 2021-05-31 2025-04-30 PHC Corporation METHOD FOR ASSESSING THE RISK OF HEMORRHAGIC STROKE USING SOLUBLE CLEC2
US20240264174A1 (en) * 2021-05-31 2024-08-08 Phc Corporation Method for evaluating risk of acute cerebral vascular disease using soluble clec2
WO2025075139A1 (ja) * 2023-10-06 2025-04-10 Ｐｈｃ株式会社 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014070942A (ja) * 2012-09-28 2014-04-21 Mitsubishi Chemical Medience Corp 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297508A1 (en) 2005-04-25 2009-12-03 University Of Yamanashi Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction
JP2007070359A (ja) 2005-09-06 2007-03-22 Univ Of Yamanashi 止血疾患治療用の医薬組成物
KR20070070359A (ko) 2005-12-29 2007-07-04 삼성전자주식회사 액정표시장치
KR101399608B1 (ko) 2007-07-27 2014-05-26 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치의 제작방법
WO2010058412A1 (en) * 2008-11-19 2010-05-27 Dilip Shrinivas Velaskar A new rapid thrombochek test kit based on whole blood screening test to detect platelet hyperaggregation at a temparature of 37°c in the clinical laboratory
US20140227265A1 (en) 2011-06-17 2014-08-14 Amgen Inc. Method of treating or ameliorating metabolic disorders using clec-2
JP6004322B2 (ja) * 2012-04-24 2016-10-05 国立大学法人 千葉大学 心血管イベントの発症リスクの検査方法
CN104285148B (zh) * 2012-05-07 2016-10-12 美迪恩斯生命科技株式会社 检测弥散性血管内凝血或感染性弥散性血管内凝血的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014070942A (ja) * 2012-09-28 2014-04-21 Mitsubishi Chemical Medience Corp 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Early recognition of sepsis-induced coagulopathy using the C2PAC index: a ratio of soluble type C lectin-like receptor 2 (sCLEC-2) level and platelet count;Hiroyasu Ishikura等;Platelets;20220124;第33卷(第6期);第935-944页 *
刘泽霖等主编.血栓性疾病的诊断与治疗.人民卫生出版社,2000,(第1版),第50-52页. *

Also Published As

Publication number Publication date
US12590978B2 (en) 2026-03-31
US20230168260A1 (en) 2023-06-01
EP4113524A4 (en) 2024-03-06
WO2021172493A1 (ja) 2021-09-02
JP7546037B2 (ja) 2024-09-05
KR20220147624A (ko) 2022-11-03
CN115190973A (zh) 2022-10-14
JPWO2021172493A1 (https=) 2021-09-02
EP4113524A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
CN115190973B (zh) 基于可溶性clec-2与血小板数的血小板活化测定方法
JP4733326B2 (ja) 患者サンプル中の止血機能障害の存在を予測する方法
CN104285148B (zh) 检测弥散性血管内凝血或感染性弥散性血管内凝血的方法
Blann et al. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis
CN105765382A (zh) 用于预测具有心血管疾病或心血管事件的风险的方法和试剂盒
CN101460852A (zh) Mrp8/14水平用于鉴别个体处于急性冠状动脉综合症风险中的应用
Karpińska et al. A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause
US20090081703A1 (en) Method for detecting deep venous thrombosis
EP4636404A2 (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
EP4350350A1 (en) Method for assessing risk of hemorrhagic stroke using soluble clec2
HK40085757A (en) Method for measuring platelet activation based on soluble clec-2 and platelet count
JP7808059B2 (ja) 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法
RU2789822C1 (ru) Способ оптимизации лабораторной диагностики тромбинемии у пациентов с инфекцией COVID-19
RU2664448C2 (ru) Способ прогнозирования развития тромбоэмболии легочной артерии у онкологических больных с флеботромбозом нижних конечностей
Zhou et al. Elevated endothelial dysfunction related biomarker levels indicate the severity and predict the incidence of sepsis
Mahmoud et al. Reliability of plasma von Willebrand factor antigen in prediction of esophageal varices in patients with liver cirrhosis
Ateş et al. The Association Between Mean Neutrophil Volume and Dipping Status in Newly Diagnosed Hypertensive Patients
WO2025075139A1 (ja) 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法
HK40127498A (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
Frelich et al. HMGB-1 as a predictor of massive transfusion protocol activation in major trauma: a prospective observational study
Ahmed et al. Elevated D-Dimer Levels, a Predictor for Thrombosis in Acute Myocardial Infarction and Unstable Coronary Artery Disease
HK40105374A (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
Li et al. Association of preoperative NT-proBNP with postoperative inflammatory factors levels among children of unrestricted left-to-right shunts congenital heart disease
Lippi et al. Laboratory diagnostics in septic disseminated intravascular coagulation
HK40106384A (en) Method for assessing risk of hemorrhagic stroke using soluble clec2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240528

Address after: Ehime Prefecture, Japan

Applicant after: Pu Heji

Country or region after: Japan

Address before: Tokyo, Japan

Applicant before: LSI MEDIENCE Corp.

Country or region before: Japan

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant